Boston Heart Diagnostics announced the launch of the Statin Induced Myopathy (SLCO1B1) Genotype test, which identifies patients who are at higher risk for developing severe myopathy (muscle aches and pain) as a side effect of statin drugs indicated to reduce low-density lipoprotein cholesterol (LDL-C) levels.
The SLCO1B1 gene is critical to the body’s uptake and metabolism of these statins. Studies show that statin users who have a one gene variation at the SLCO1B1 location are about five times more likely to suffer myopathy, and users with two gene variations are 18-times more likely to experience myopathy.
This risk is especially marked in those receiving high doses of Zocor (simvastatin; Merck) and Lipitor (atorvastatin; Pfizer). The healthcare provider should consider using lower doses of water-soluble statins such as Pravachol (pravastatin sodium; Bristol-Myers Squibb) <20mg/day, Livalo (pitavastatin; Kowa Pharamceuticals) <2mg/day, Crestor (rosuvastatin; AstraZeneca) <10mg/day, or Lescol (fluvastatin sodium; Novartis) <20mg/day, and adding Zetia (ezetimibe; Merck) or Welchol (colesevelam; Daiichi Sankyo) therapy to augment LDL-C lowering response if needed.
For more information call (508) 877-8711 or visit www.bostonheartdiagnostics.com.